“Nizatidine”的意思、由来-开放百科全书

Nizatidine is a histamine H₂ receptor antagonist that inhibits stomach acid production, and is commonly used in the treatment of peptic ulcer disease and gastroesophageal reflux disease.

It was patented in 1980 and approved for medical use in 1987.^[1] It was developed by Eli Lilly. Brand names include Tazac and Axid.

Medical use

Nizatidine is used to treat duodenal ulcers, gastric ulcers, and gastroesophageal reflux disease (GERD/GORD), and to prevent stress ulcers.^[2]

Adverse effects

Side effects are uncommon, usually minor, and include diarrhea, constipation, fatigue, drowsiness, headache, and muscle aches.^[2]

History and development

Nizatidine was developed by Eli Lilly, and was first marketed in 1987. It is considered to be equipotent with ranitidine and differs by the substitution of a thiazole ring in place of the furan ring in ranitidine. In September 2000, Eli Lilly announced they would sell the sales and marketing rights for Axid to Reliant Pharmaceuticals.^[3] Subsequently, Reliant developed the oral solution of Axid, marketing this in 2004, after gaining approval from the U.S. Food and Drug Administration (FDA).^[4] However, a year later, they sold rights of the Axid Oral Solution (including the issued patent^[5] protecting the product) to Braintree Laboratories.^[6]

Nizatidine proved to be the last new histamine H₂ receptor antagonist introduced prior to the advent of proton pump inhibitors.{{citation needed|date=January 2016}}

See also

References

1. ^{{cite book |last1=Fischer |first1=Jnos |last2=Ganellin |first2=C. Robin |title=Analogue-based Drug Discovery |date=2006 |publisher=John Wiley & Sons |isbn=9783527607495 |page=44 |url=https://books.google.ca/books?id=FjKfqkaKkAAC&pg=PA444 |language=en}}
2. ^¹²{{cite web|url=http://livertox.nih.gov/Nizatidine.htm |title=Nizatidine |publisher=Livertox.nih.gov |date= |accessdate=2015-10-11}}
3. ^ {{webarchive |url=https://web.archive.org/web/20080526223021/http://www.encyclopedia.com/doc/1G1-65062714.html?Q=%22axid%22 |date=May 26, 2008 }}
4. ^ {{webarchive |url=https://web.archive.org/web/20131226093839/http://www.reliantrx.com/investor/press_releases/072604.htm |date=December 26, 2013 }}
5. ^{{cite web|url=http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO1&Sect2=HITOFF&d=PALL&p=1&u=%2Fnetahtml%2FPTO%2Fsrchnum.htm&r=1&f=G&l=50&s1=6930119.PN.&OS=PN/6930119&RS=PN/6930119 |title=United States Patent: 6930119 |publisher=Patft.uspto.gov |date= |accessdate=2015-10-11}}
6. ^ {{webarchive |url=https://web.archive.org/web/20070814071007/http://www.reliantrx.com/investor/press_releases/063005.htm |date=August 14, 2007 }}

词条	Nizatidine
释义	Medical use Adverse effects History and development See also References External links {{Drugbox \| Verifiedfields = changed \| verifiedrevid = 457657906 \| IUPAC_name = (E)-1-N{{'}}-[2-[[2-[(dimethylamino)methyl]-1,3-thiazol-4-yl]methylsulfanyl]ethyl]-1-N-methyl-2-nitroethene-1,1-diamine \| image = Nizatidine.svg \| width = 260 \| tradename = Axid, Tazac \| Drugs.com = {{drugs.com\|monograph\|nizatidine}} \| MedlinePlus = a694030 \| licence_US = Nizatidine \| pregnancy_AU = B3 \| legal_AU = S4 \| legal_UK = POM \| legal_US = Rx \| legal_US_comment = and OTC^[1] \| routes_of_administration = By mouth \| bioavailability = >70% \| protein_bound = 35% \| metabolism = Liver \| elimination_half-life = 1–2 hours \| excretion = Kidney \| IUPHAR_ligand = 7248 \| CAS_number_Ref = {{cascite\|correct\|??}} \| CAS_number = 76963-41-2 \| ATC_prefix = A02 \| ATC_suffix = BA04 \| ATC_supplemental = \| PubChem = 3033637 \| DrugBank_Ref = {{drugbankcite\|correct\|drugbank}} \| DrugBank = DB00585 \| ChemSpiderID_Ref = {{chemspidercite\|correct\|chemspider}} \| ChemSpiderID = 2298266 \| UNII_Ref = {{fdacite\|correct\|FDA}} \| UNII = P41PML4GHR \| KEGG_Ref = {{keggcite\|correct\|kegg}} \| KEGG = D00440 \| ChEBI_Ref = {{ebicite\|changed\|EBI}} \| ChEBI = 7601 \| ChEMBL_Ref = {{ebicite\|correct\|EBI}} \| ChEMBL = 653 \| C=12 \| H=21 \| N=5 \| O=2 \| S=2 \| molecular_weight = 331.46 g/mol \| smiles = [O-][N+](=O)\\C=C(/NC)NCCSCc1nc(sc1)CN(C)C \| StdInChI_Ref = {{stdinchicite\|correct\|chemspider}} \| StdInChI = 1S/C12H21N5O2S2/c1-13-11(6-17(18)19)14-4-5-20-8-10-9-21-12(15-10)7-16(2)3/h6,9,13-14H,4-5,7-8H2,1-3H3/b11-6+ \| StdInChIKey_Ref = {{stdinchicite\|correct\|chemspider}} \| StdInChIKey = SGXXNSQHWDMGGP-IZZDOVSWSA-N }} Nizatidine is a histamine H₂ receptor antagonist that inhibits stomach acid production, and is commonly used in the treatment of peptic ulcer disease and gastroesophageal reflux disease. It was patented in 1980 and approved for medical use in 1987.^[1] It was developed by Eli Lilly. Brand names include Tazac and Axid. Medical use {{main\|H2 antagonist}} Nizatidine is used to treat duodenal ulcers, gastric ulcers, and gastroesophageal reflux disease (GERD/GORD), and to prevent stress ulcers.^[2] Adverse effects Side effects are uncommon, usually minor, and include diarrhea, constipation, fatigue, drowsiness, headache, and muscle aches.^[2] History and development Nizatidine was developed by Eli Lilly, and was first marketed in 1987. It is considered to be equipotent with ranitidine and differs by the substitution of a thiazole ring in place of the furan ring in ranitidine. In September 2000, Eli Lilly announced they would sell the sales and marketing rights for Axid to Reliant Pharmaceuticals.^[3] Subsequently, Reliant developed the oral solution of Axid, marketing this in 2004, after gaining approval from the U.S. Food and Drug Administration (FDA).^[4] However, a year later, they sold rights of the Axid Oral Solution (including the issued patent^[5] protecting the product) to Braintree Laboratories.^[6] Nizatidine proved to be the last new histamine H₂ receptor antagonist introduced prior to the advent of proton pump inhibitors.{{citation needed\|date=January 2016}} See also Famotidine (Pepcid) — another popular H₂ receptor antagonist References 1. ^{{cite book \|last1=Fischer \|first1=Jnos \|last2=Ganellin \|first2=C. Robin \|title=Analogue-based Drug Discovery \|date=2006 \|publisher=John Wiley & Sons \|isbn=9783527607495 \|page=44 \|url=https://books.google.ca/books?id=FjKfqkaKkAAC&pg=PA444 \|language=en}} 2. ^¹²{{cite web\|url=http://livertox.nih.gov/Nizatidine.htm \|title=Nizatidine \|publisher=Livertox.nih.gov \|date= \|accessdate=2015-10-11}} 3. ^ {{webarchive \|url=https://web.archive.org/web/20080526223021/http://www.encyclopedia.com/doc/1G1-65062714.html?Q=%22axid%22 \|date=May 26, 2008 }} 4. ^ {{webarchive \|url=https://web.archive.org/web/20131226093839/http://www.reliantrx.com/investor/press_releases/072604.htm \|date=December 26, 2013 }} 5. ^{{cite web\|url=http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO1&Sect2=HITOFF&d=PALL&p=1&u=%2Fnetahtml%2FPTO%2Fsrchnum.htm&r=1&f=G&l=50&s1=6930119.PN.&OS=PN/6930119&RS=PN/6930119 \|title=United States Patent: 6930119 \|publisher=Patft.uspto.gov \|date= \|accessdate=2015-10-11}} 6. ^ {{webarchive \|url=https://web.archive.org/web/20070814071007/http://www.reliantrx.com/investor/press_releases/063005.htm \|date=August 14, 2007 }} External links Dailymed.nlm.nih.gov Axid @ FDA Axid Oral Solution {{H2-receptor antagonist}}{{Histaminergics}} 5 : Eli Lilly and Company\|H2 receptor antagonists\|Nitroethenes\|Thiazoles\|Thioethers
随便看	Microsphere (disambiguation) Microsphere (software company) Microspherophakia Microsplenium Microsporosis Microsporum gallinae Microsporum gallinae/version 2 Microsporum nanum Micro sprint MicroSSD Microstates and Europe Microstates and the EU MicroStation 8.11.7.443 by Bentley Systems, Incorporated Microstega homoculorum Microstephium niveum Microstephium populifolium Microsternarchus Microsternarchus bilineatus Microsteus Microstigmata Microstigmus Microstola ammoscia Microstoma protractum Microstomatichthyoborus Microstomus shuntovi

Medical use

Adverse effects

History and development

See also

References

External links